ENTBF - Entheon Biomedical Corp.
| Previous Close | 0.0173 |
| Open | 0.0170 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0170 - 0.0170 |
| 52 Week Range | 0.0100 - 0.0810 |
| Volume | |
| Avg. Volume | 5,280 |
| Market Cap | 1.07M |
| Beta (5Y Monthly) | 1.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings Date | Oct 28, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireEhave Shareholder from CEO Ben Kaplan and Corporate Update
MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in seve
NewsfileEntheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news release dated June 7, 2022, it has completed the sale of its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. pursuant to an asset purchase agreement for a purchase price of CAD$1,000,000 (the "Transaction"). ...
- Newsfile
Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a definitive agreement (the "Agreement") dated June 7, 2022 with Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. ("Cybin"), pursuant to which the Company has agreed to sell its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to the Purchaser (the "Transaction") for ...
- GlobeNewswire
Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research
AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinicGenetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy MIAMI, June 01, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision med